Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N Sternberg

Showing results (371-380 of 564) with videos related to

Pageof 57
Sort By:
JAMIA Open|June 19, 2026
Enhancing the quality and trustworthiness of large language model-generated summaries of clinical oncology literatureArnulf Stenzl, Eamonn Rogers, Sophia Ananiadou, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 16, 2012
Effect of abiraterone acetate on fatigue in patients with metastatic castration-resistant prostate cancer after docetaxel chemotherapyC N Sternberg, A Molina, S North, et al.
BJU International|March 30, 2010
Management of prostate cancer in older men: recommendations of a working group of the International Society of Geriatric OncologyJean-Pierre Droz, Lodovico Balducci, Michel Bolla, et al.
Critical Reviews in Oncology/Hematology|October 20, 2009
Background for the proposal of SIOG guidelines for the management of prostate cancer in senior adultsJean-Pierre Droz, Lodovico Balducci, Michel Bolla, et al.
Anticancer Research|November 2, 2010
Clinical and molecular determinants of survival in pancreatic cancer patients treated with second-line chemotherapy: results of an Italian/Swiss multicenter surveyA Mancuso, S Sacchetta, P C Saletti, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 16, 2001
Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer Protocol no. 30924C N Sternberg, P H de Mulder, J H Schornagel, et al.
Prostate Cancer and Prostatic Diseases|February 22, 2022
Real-world patient characteristics associated with survival of 2 years or more after radium-223 treatment for metastatic castration-resistant prostate cancer (EPIX study)Daniel J George, Neeraj Agarwal, Oliver Sartor, et al.
Prostate Cancer and Prostatic Diseases|September 14, 2021
Impact of enzalutamide on patient-reported fatigue in patients with prostate cancer: data from the pivotal clinical trialsBertrand F Tombal, Stephen J Freedland, Andrew J Armstrong, et al.
European Journal of Cancer (Oxford, England : 1990)|August 27, 2013
Effect of abiraterone acetate treatment on the quality of life of patients with metastatic castration-resistant prostate cancer after failure of docetaxel chemotherapyStephen Harland, John Staffurth, Arturo Molina, et al.
Oncology|March 3, 2005
Phase III trial of satraplatin, an oral platinum plus prednisone vs. prednisone alone in patients with hormone-refractory prostate cancerC N Sternberg, P Whelan, J Hetherington, et al.
Pageof 57

Showing results (371-380 of 564) with videos related to

Sort By:
Pageof 57
JAMIA Open|June 19, 2026
Enhancing the quality and trustworthiness of large language model-generated summaries of clinical oncology literatureArnulf Stenzl, Eamonn Rogers, Sophia Ananiadou, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 16, 2012
Effect of abiraterone acetate on fatigue in patients with metastatic castration-resistant prostate cancer after docetaxel chemotherapyC N Sternberg, A Molina, S North, et al.
BJU International|March 30, 2010
Management of prostate cancer in older men: recommendations of a working group of the International Society of Geriatric OncologyJean-Pierre Droz, Lodovico Balducci, Michel Bolla, et al.
Critical Reviews in Oncology/Hematology|October 20, 2009
Background for the proposal of SIOG guidelines for the management of prostate cancer in senior adultsJean-Pierre Droz, Lodovico Balducci, Michel Bolla, et al.
Anticancer Research|November 2, 2010
Clinical and molecular determinants of survival in pancreatic cancer patients treated with second-line chemotherapy: results of an Italian/Swiss multicenter surveyA Mancuso, S Sacchetta, P C Saletti, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 16, 2001
Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer Protocol no. 30924C N Sternberg, P H de Mulder, J H Schornagel, et al.
Prostate Cancer and Prostatic Diseases|February 22, 2022
Real-world patient characteristics associated with survival of 2 years or more after radium-223 treatment for metastatic castration-resistant prostate cancer (EPIX study)Daniel J George, Neeraj Agarwal, Oliver Sartor, et al.
Prostate Cancer and Prostatic Diseases|September 14, 2021
Impact of enzalutamide on patient-reported fatigue in patients with prostate cancer: data from the pivotal clinical trialsBertrand F Tombal, Stephen J Freedland, Andrew J Armstrong, et al.
European Journal of Cancer (Oxford, England : 1990)|August 27, 2013
Effect of abiraterone acetate treatment on the quality of life of patients with metastatic castration-resistant prostate cancer after failure of docetaxel chemotherapyStephen Harland, John Staffurth, Arturo Molina, et al.
Oncology|March 3, 2005
Phase III trial of satraplatin, an oral platinum plus prednisone vs. prednisone alone in patients with hormone-refractory prostate cancerC N Sternberg, P Whelan, J Hetherington, et al.
Pageof 57